Seizure types

Epilepsy Foundation Launches New TV Spots to Promote Proper Seizure First Aid

Retrieved on: 
Monday, March 4, 2019
Health, Medicine, Epilepsy, Clinical medicine, Epileptic seizure, RTT, Seizure types

The PSAs are part of the Epilepsy Foundation's #ShareMySeizure education initiative designed to help improve the general public's awareness about seizure recognition and first aid.

Key Points: 
  • The PSAs are part of the Epilepsy Foundation's #ShareMySeizure education initiative designed to help improve the general public's awareness about seizure recognition and first aid.
  • "The importance of public education about epilepsy and Seizure First Aid cannot be overstated," said Philip M. Gattone, M.Ed., president and CEO of the Epilepsy Foundation.
  • "It is critical that everyone know Seizure First Aid to help people with epilepsy feel safer in their communities.
  • Over a lifetime, one in 10 people will have a seizure, and one in 26 will be diagnosed with epilepsy.

NeurologyLive™ Launches “Epilepsy: Current Trends and Treatments for Focal Seizures”

Retrieved on: 
Wednesday, February 27, 2019
Health, Hospitals, Other Health, Research, Other Science, Science, Medicine, Clinical medicine, Health, Epilepsy, Epileptic seizure, Seizure types

NeurologyLive , a digital and print multimedia platform dedicated to providing health care professionals treating neurological diseases direct access to expert, practice-changing news and insights in neurology, presents its most recent Peer Exchange panel discussion, Epilepsy: Current Trends and Treatments for Focal Seizures.

Key Points: 
  • NeurologyLive , a digital and print multimedia platform dedicated to providing health care professionals treating neurological diseases direct access to expert, practice-changing news and insights in neurology, presents its most recent Peer Exchange panel discussion, Epilepsy: Current Trends and Treatments for Focal Seizures.
  • The video series welcomes several experts in the treatment and management of epilepsy who provide peer-to-peer dialogue, authoritative insights, opinions and perspectives on current trends and available treatments for focal seizures.
  • The first segment of this Peer Exchange series provides an overview of epilepsy and the current understanding of it, as well as an in-depth discussion about the pharmacologic treatments for focal seizures.
  • NeurologyLive is part of the Cranbury, New Jersey-based MJH Associates, Inc., health care enterprise, which includes OncLive and CURE magazine.

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

Retrieved on: 
Wednesday, January 16, 2019
Health, Seizure types, RTT, Pharmaceutical industry, Medicine, Epileptic seizure, Focal seizure, Generic drug, Food and Drug Administration

"We know there has been past interest in developing a generic alternative to this product.

Key Points: 
  • "We know there has been past interest in developing a generic alternative to this product.
  • We're especially focused on new policies aimed at making the generic review process more predictable, efficient and lower cost so we can entice more generic firms to enter this space, and help facilitate more generic drug launches after generic approvals.
  • Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness.
  • The FDA has continued to emphasize that even in the case of limited distribution programs, there should be a path forward for generic drug development.

At AES 2018 Cognizance Biomarkers Unveils Data Showing It Can Accurately Distinguish between Epileptic and Psychogenic Nonepileptic Seizures

Retrieved on: 
Monday, December 3, 2018
Seizure types, Medicine, Health, Epilepsy, Abnormal psychology, Psychogenic non-epileptic seizure, Neurology, Epileptic seizure

His former laboratory at the University of Pennsylvania conducted key studies of Cognizance Biomarkers' approach.

Key Points: 
  • His former laboratory at the University of Pennsylvania conducted key studies of Cognizance Biomarkers' approach.
  • Individuals with psychogenic nonepileptic seizures are especially at risk for an epilepsy misdiagnosis.
  • Prior clinical studies have confirmed the ability of the Cognizance neuroinflammatory biomarker test to distinguish actual seizures from seizure-like events.
  • The results we are presenting today address one of the most vexing diagnostic issues in epilepsydifferentiating true epileptic seizures from similar-seeming psychogenic nonepileptic events.

Epilepsy Foundation And Alquemie Product Development Group Partner To End Epilepsy

Retrieved on: 
Tuesday, November 20, 2018
Medicine, Epilepsy, Health, Epileptic seizure, Clinical medicine, Seizure types

During the partnership, A.P.D.G will donate25 percent of their net sales from the product to the Epilepsy Foundation's nationwide campaign "Let's Use Our Brains to End Epilepsy" to fund research, advocacy and education.

Key Points: 
  • During the partnership, A.P.D.G will donate25 percent of their net sales from the product to the Epilepsy Foundation's nationwide campaign "Let's Use Our Brains to End Epilepsy" to fund research, advocacy and education.
  • "I am truly honored to partner with the Epilepsy Foundation, an organization that has played an integral role in my life while living with epilepsy," said Rhonda M. Davis, founder and chemist of A.P.D.G.
  • has teamed up with us to help raise awareness about epilepsy," said Philip M. Gattone, president and CEO of the Epilepsy Foundation.
  • To create awareness and inspire action, the Epilepsy Foundation launchedLet's Use Our Brains to End Epilepsy to raise awareness about epilepsy and change the conversation around seizures.The campaign is built around the fact that epilepsy can affect anyone with a brain, and anyone with a brain can affect epilepsy.

Lennox Gastaut Syndrome Insights, Epidemiology and Market Forecast, 2016-2027 featuring GSK, Meds Pharma, Roche, Lundbeck, Janssen Pharma, Eisai Zogenix International & Takeda

Retrieved on: 
Friday, November 9, 2018
Neurological disorders, Neurology, Lennox–Gastaut syndrome, Special education, Lennox, Medicine, Syndromes, Seizure types, Epilepsy

The "Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lennox Gastaut Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The Lennox Gastaut Syndrome market report gives the thorough understanding of the Lennox Gastaut Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
  • It also provides treatment algorithms and treatment guidelines for Lennox Gastaut Syndrome in the US, Europe, and Japan.

UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

Retrieved on: 
Tuesday, May 22, 2018
Epilepsy, Neurology, UCB, Health, Seizure types, Medicine, Epilepsy syndromes, Frontal lobe epilepsy

Epilepsy is the most common serious disease of the brain,[1] affecting 65 million people around the world.

Key Points: 
  • Epilepsy is the most common serious disease of the brain,[1] affecting 65 million people around the world.
  • [1]
    "This World Health Assembly can be a turning point for the epilepsy community.
  • "We share a joint commitment to provide additional value to people living with epilepsy around the world.
  • At UCB, we are inspired by patients, and driven by science in our commitment to support people with epilepsy.